Biacore launches its own operation in China

21 May 2006

Uppsala, Sweden-based Biacore International AB, a supplier of systems for protein interaction analysis, says that it has formally launched its own operation in China, and is taking over full business responsibility for its products there. The new organization is designed to take Biacore's business to the next stage of its development in the rapidly growing market for life science instrumentation in China.

The new Chinese operation will be headed by Peter Lee, the former regional sales manager for GE Healthcare in Southern China. He will lead a team of six people based in Shanghai that will be responsible for the sales, marketing, applications support and service of Biacore's systems. In the outlying areas of the country, Biacore will be supported by a network of local dealers and distributors. The organization will target customers in the life science research, pharmaceutical and biotechnology and food sectors.

The market for life science instrumentation in China was estimated to be worth $1.6 billion in 2005, having more than doubled in value since 1998. Over the next several years, the Chinese market for these products is expected to grow significantly as the government continues to invest in new centers of excellence in the areas of proteomics and genomics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight